Fishawack Health announces a new CEO to lead the organization through its next stage of growth. Oliver Dennis has stepped down from his role as CEO and Gail Flockhart, Group President, will serve as interim CEO. Jonathan (Jon) Koch will join the group as our new CEO, leading the organization through its next stage of growth from October 1st.
“Oliver Dennis has led our business for more than 20 years and was instrumental to our incredible growth, now with 1,300 employees spanning Europe, the U.S., and Asia, and an enviable client roster,” said Flockhart. “He leaves an important legacy, and I personally want to share a deep-felt thank you for creating a dynamic and successful business that we can all be proud to be a part of.”
We are delighted to announce that Jon Koch will join Fishawack Health as our new CEO at the beginning of October. Jon has extensive experience in drug development and organizational leadership and leads with a people-centric philosophy. He is departing the publicly listed organization Henry Schein’s Global Dental Group, where he served as Senior Vice President and CEO of their largest healthcare division and leading technology business.
Jon has spent a large proportion of his career at Covance (now LabCorp Drug Development), serving last as Group President of clinical development and commercialization services, leading more than 11,000 employees across dozens of countries. During this time, he developed a passion for bringing therapies to market that positively impact patient outcomes.
Jon will usher in a new phase of growth at Fishawack Health, drawing on his exceptional experience leading large global, customer-centered organizations of scale in the life science services sector to build a sustainable future for the organization.
Flockhart, who joined Fishawack Health in 2009 and has held various leadership roles at the company and other healthcare and pharmaceutical organizations, remains in her role as Group President. She will work closely with Jon and the Executive Leadership team to move the organization forward in the U.S. domestic and global marketplace as we advance our plan for commercialization services to support our clients in global pharmaceuticals, biotech, and the medical devices industry. “I am excited for the next phase of growth, where we will focus on building and retaining talented teams and providing the processes and infrastructure needed for efficient and effective delivery of our full commercialization service set,” adds Flockhart.
In the coming weeks, we will share more about Jon’s experience and vision and reveal more exciting news about current and planned investments in our teams. These announcements will further cement our commitment to become an employer of choice and continue to be great partners for our clients across the life science industry.